Morocco to Strengthen Pharmaceutical Oversight

Rabat – The Government Council approved on Wednesday a draft decree concerning the conditions and procedures for determining the public sale prices of locally manufactured and imported medicines.

According to a statement from the Ministry Delegate in Charge of Relations with Parliament the text concerns Draft Decree No. 2.25.631, which amends and supplements Decree No. 2.13.852, issued on December 18, 2013.

Presented by the Minister of Health and Social Protection, the new measures seek to make medicines more affordable by revising pricing mechanisms, particularly for drugs whose prices no longer reflect market realities.

Authorities say the reform is designed to strike a balance between ensuring patients have access to affordable treatments and maintaining the sustainability of the pharmaceutical industry.

The initiative comes as Morocco continues to implement major healthcare reforms launched under the royal project for universal social protection.

Expanding health insurance coverage has increased demand for medicines, placing greater emphasis on keeping treatment costs within reach for households while ensuring a stable supply of pharmaceutical products. 

Authorities have stressed that stronger oversight is essential as the Moroccan pharmaceutical market continues to grow and diversify, with increasing numbers of innovative treatments and generic medicines becoming available.

The government’s approach combines affordability with stricter regulation, reflecting a broader strategy to modernize healthcare governance while reinforcing patient protection. 

Officials argue that lowering prices alone is not sufficient without ensuring that medicines remain safe, effective, and consistently available across the country.

But as universal health coverage expands, the country is likely to face growing pressure to guarantee not only affordable access to treatment but also a reliable pharmaceutical supply capable of meeting rising demand.